# Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

> **NCT04451954** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 210 (actual)

## Conditions studied

- Influenza Immunisation
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 1
- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 1 and adjuvant
- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 2
- **BIOLOGICAL:** Quadrivalent RIV with H3 strain 2 and adjuvant
- **BIOLOGICAL:** Quadrivalent RIV with 2018-2019 NH H3 strain
- **BIOLOGICAL:** Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant

## Key facts

- **NCT ID:** NCT04451954
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-02
- **Primary completion:** 2021-09-20
- **Final completion:** 2021-09-20
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04451954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04451954, "Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04451954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*